The safety and efficacy of semaglutide in people with schizophrenia spectrum disorders: systematic review and meta-analysis of randomised controlled trials

Background People with schizophrenia spectrum disorders (SSDs) experience high rates of obesity and metabolic dysfunction, contributing substantially to excess morbidity and mortality. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide and tirzepatide have demonstrated subst...

Повний опис

Бібліографічні деталі

Автори:	Mike Trott, Urska Arnautovska, Donni Johnston, Gabrielle Ritchie, Dan Siskind
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Cambridge University Press 2026-05-01
Серія:	BJPsych Open
Предмети:	Psychotic disorders/schizophrenia randomised controlled trial clinical trials systematic review meta-analysis
Онлайн доступ:	https://www.cambridge.org/core/product/identifier/S2056472426120018/type/journal_article
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!